Ignite Creation Date:
2025-12-24 @ 7:19 PM
Ignite Modification Date:
2026-01-17 @ 8:16 PM
Study NCT ID:
NCT03059303
Status:
TERMINATED
Last Update Posted:
2017-12-22
First Post:
2017-02-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)
Sponsor:
Janssen Research & Development, LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-02-20
Start Date Type:
ACTUAL
Primary Completion Date:
2017-04-24
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-04-24
Completion Date Type:
ACTUAL
First Submit Date:
2017-02-17
First Submit QC Date:
None
Study First Post Date:
2017-02-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-12-21
Last Update Post Date:
2017-12-22
Last Update Post Date Type:
ACTUAL